Laryngeal edema as a symptom of local cytokine release syndrome after BCMA-targeting CAR-T therapy for relapsed and refractory multiple myeloma

[1]  D. Siegel,et al.  I-OPen: inferior outcomes of penta-refractory compared to penta-exposed multiple myeloma patients , 2022, Blood Cancer Journal.

[2]  H. Shimada,et al.  Cervical Edema Extending to the Larynx as Local Cytokine Release Syndrome Following Chimeric Antigen Receptor T-Cell Therapy in a Boy with Refractory Acute Lymphoblastic Leukemia , 2022, Case Reports in Oncology.

[3]  Dagan Zhang,et al.  Case Report: Local Cytokine Release Syndrome in an Acute Lymphoblastic Leukemia Patient After Treatment With Chimeric Antigen Receptor T-Cell Therapy: A Possible Model, Literature Review and Perspective , 2021, Frontiers in Immunology.

[4]  J. Rasko,et al.  The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma , 2020, Signal Transduction and Targeted Therapy.

[5]  He Huang,et al.  Severe dyspnea caused by rapid enlargement of cervical lymph node in a relapsed/refractory B-cell lymphoma patient following chimeric antigen receptor T-cell therapy , 2018, Bone Marrow Transplantation.

[6]  Delong Liu,et al.  Cytokine release syndrome: grading, modeling, and new therapy , 2018, Journal of Hematology & Oncology.

[7]  M. Sadelain,et al.  CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade , 2018, Nature Medicine.

[8]  P. Richardson,et al.  CD38 antibodies in multiple myeloma: back to the future. , 2018, Blood.

[9]  P. Moreau,et al.  Frontline therapy of multiple myeloma. , 2015, Blood.